Synlogic (A3EWCN) Stock Price & Analysis
A3EWCN Stock Chart & Stats
- Day’s Range
- EUR 1.34 - EUR 1.45
- 52-Week Range
- EUR 1.34 - EUR 1.45
- Previous Close
- EUR 1.45
- Volume
- N/A
- Average Volume (3M)
- 0
- Market Cap
- EUR 10.49M
- Enterprise Value
- EUR 4.96M
- Total Cash (Recent Filing)
- EUR 13.18M
- Total Debt (Recent Filing)
- EUR 0
- Price to Earnings (P/E)
- ―
- Beta
- N/A
- Next Earnings
- N/A
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Debt-free Balance Sheet
Eliminating debt reduces interest and refinancing pressure while preserving flexibility to allocate resources toward research and development. Positive equity provides some cushion, making the company less exposed to leverage-driven financial stress as it advances its clinical programs.
Reduced Cash Burn
The sharp reduction in operating cash burn indicates materially tighter cost discipline, which can extend the company’s ability to fund development activities. Although cash flow remains negative, the improved trajectory lowers near-term funding needs and supports more efficient capital use.
Merger-funded Development Runway
The planned financing could provide substantial resources for Phase 2 development and extend operating runway through 2029. Greater funding visibility may allow the combined business to pursue clinical milestones without relying immediately on repeated capital raises.
Bears Say
No Recurring Commercial Revenue
The absence of meaningful recurring revenue leaves the company dependent on financing, collaborations, or future clinical success rather than an established commercial engine. This limits earnings visibility and means operating leverage cannot yet support development spending internally.
Persistent Negative Free Cash Flow
Continued negative free cash flow shows that the business is not self-sustaining and must use existing resources or obtain external funding to continue operations. This remains a durable constraint because clinical development requires spending before potential product revenue.
Shrinking Asset Base And Negative Returns
The substantial contraction in assets, combined with persistently negative returns on equity, reflects ongoing value erosion and reduced financial scale. A smaller resource base can limit strategic flexibility and leaves less balance-sheet support for advancing future development programs.
Synlogic News
A3EWCN FAQ
What was Synlogic’s price range in the past 12 months?
What is Synlogic’s market cap?
When is Synlogic’s upcoming earnings report date?
How were Synlogic’s earnings last quarter?
Is Synlogic overvalued?
Does Synlogic pay dividends?
What is Synlogic’s EPS estimate?
How many shares outstanding does Synlogic have?
What happened to Synlogic’s price movement after its last earnings report?
Which hedge fund is a major shareholder of Synlogic?
What is the TipRanks Smart Score and how is it calculated?
Company Description
Synlogic
Synlogic, Inc. does not have significant operations. It was previously engaged in the discovery and development of synthetic biotics to treat metabolic diseases. Synlogic, Inc. is based in Winchester, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Mary Beth Dooley
- Employees
- 1
- Website
- www.synlogictx.com
- Address
- PO Box 30, Winchester, MA, 01890, US
Synlogic (A3EWCN) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 8 | 2 | 7 |
| Technical Analysis | 1 | 1 | 3 |
| Moving Averages | 7 | 1 | 4 |